天津医药

天津医药 ›› 2022, Vol. 50 ›› Issue (3): 324-327.doi: 10.11958/20212075

• 综述 • 上一篇    下一篇

单细胞测序技术在淋巴瘤中的应用研究进展

司君齐，袁田，李世俊，田晨   

  1. 1天津医科大学肿瘤医院，国家肿瘤临床医学研究中心，天津市肿瘤防治重点实验室，天津市恶性肿瘤医学研究中心（邮编300060）；2新疆维吾尔自治区和田地区人民医院肿瘤内科
  • 收稿日期:2021-09-08 修回日期:2021-11-10 出版日期:2022-03-15 发布日期:2022-03-15
  • 基金资助:
    天津市卫生健康科技项目（ZC20171）；国家自然科学基金资助项目（81800148）

Research progress of single cell sequencing in lymphoma

SI Junqi, YUAN Tian, LI Shijun, TIAN Chen   

  1. 1 Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China; 2 Department of Oncology, Hotan District People’s Hospital, Xinjiang Uygur Autonomous Region
  • Received:2021-09-08 Revised:2021-11-10 Published:2022-03-15 Online:2022-03-15

PDF (PC)

2634

摘要： 传统的高通量测序技术对肿瘤患者进行表型分析后所获得的分子图谱仅代表大多数细胞的平均表型，因此不可避免地会导致大量信息丢失。为了弥补这一不足，单细胞测序技术应运而生。作为一项变革性技术，其可在单个细胞水平上进行分析，从而深入了解肿瘤细胞间微环境的差异，并有助于肿瘤靶向药物的研发。目前，该技术已应用于多种淋巴瘤，包括霍奇金淋巴瘤及非霍奇金淋巴瘤，体现了较大的临床应用价值。

关键词: 淋巴瘤, 序列分析, 单细胞测序, 肿瘤异质性

Abstract: The traditional high-throughput sequencing technology obtained after phenotyping analysis of tumor patients only represents the average phenotype of most cells, so a large amount of information will inevitably be lost. In order to make up for this shortcoming, single cell sequencing (SCS) technology arises at the right moment. As a revolutionary technology, it can analyze individual cells to gain insight into the differences in the microenvironment between tumor cells, and help the development of tumor targeted drugs. At present, this technology has been applied to a variety of lymphomas, including Hodgkin's lymphoma and non-Hodgkin's lymphoma, and shows great clinical application value.

Key words: lymphoma, sequence analysis, single cell sequencing, tumor heterogeneity